Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis
NCT ID: NCT02845804
Last Updated: 2016-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1533 participants
OBSERVATIONAL
2015-07-31
2021-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™ stent
2. To evaulate the long-term efficacy and safety of coronary stenting with the Xience Xpedition™/Alpine™ stent
3. To compare the long-term efficacy and safety of coronary stenting between the Xience Xpedition™/Alpine ™ stent and other contemporary drug-eluting stents which had established their own registry
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice
NCT02042300
Alpine vs. Xpedition: Evaluation of Stent Delivery System
NCT03451617
Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)
NCT01605721
Evaluation of Everolimus-Eluting Stents (The K-XIENCE Registry)
NCT01350869
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)
NCT03484234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI
Target vessl failure
Composite rate of cardiac death and any MI, 3 years
Composite rate of all death and any MI
Composite rate of all death, any MI, and any repeat revascularization
Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alpine
The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™
Alpine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alpine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyo-Soo Kim
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyo-soo Kim, MD, PhD
Role: STUDY_CHAIR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kangwon National University Hospital
Chuncheon, Gangwon-do, South Korea
Wonju Severance Christian Hospital
Wŏnju, Gangwon-do, South Korea
Sejong General Hospital
Bucheon-si, Gyeonggi-do, South Korea
Hallym University Sacred Heart Hospital
Anyang, , South Korea
Busan Paik Hospital
Busan, , South Korea
Kosin University Gospel Hospital
Busan, , South Korea
Dankook University Hospital
Cheonan, , South Korea
SoonChunHyang University Cheonan Hospital
Cheonan, , South Korea
Yongnam University Medical Center
Daegu, , South Korea
Chonnam National University Hospital
Gwangju, , South Korea
Wonkwang University Hospital
Iksan, , South Korea
Inha University Hospital
Inchon, , South Korea
Chungbuk National University Hospital
Jeonju, , South Korea
Presbyterian Medical Center
Jeonju, , South Korea
Seoul National University Bundang Hospital
Seongnam, , South Korea
Gangbuk Samsung Hospital
Seoul, , South Korea
Hanyang University Medical Center
Seoul, , South Korea
Kangdong Sacred Heart Hospital
Seoul, , South Korea
Seoul Boramae Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yong-Hoon Kim
Role: primary
Jung-Han Yoon
Role: primary
Young-Jin Choi
Role: primary
Sang-Ho Jo, MD,PhD
Role: primary
Tae-Hyun Yang
Role: primary
Jeong Ho Heo
Role: primary
Byung-Eun Park, MD,PhD
Role: primary
Sang-Ho Park
Role: primary
Myung-Ho Jeong
Role: primary
In-Ho Chae, MD,PhD
Role: primary
Ki-Cheol Sung, MD,PhD
Role: primary
Young-Hyo Lim
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HOST-ALPINE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.